8/7/2019 Bracco Ppt Presentation_1
1/18
Confidential & Proprietary
8/7/2019 Bracco Ppt Presentation_1
2/18
Confidential & Proprietary
Additional findings from the IMPACT Study
A Comparison of the Efficacy & Safetyof Iopamidol-370 and Iodixanol-320 inPatients Undergoing Multidetector-row
Computed Tomography
D ushyant V. Sahani, Gilles Sowlez, M D , Ke-Min Chen, M D , Luigi Lepanto, M D , Jian-Rong Xu, M D , Rendon C. Nelson, M D , Luigi Grazioli, M D , Angelo Vanzulli, M D , Jay
P. Heiken, M D , and the Investigators of the IMPACT Study
8/7/2019 Bracco Ppt Presentation_1
3/18
Confidential & Proprietary
Reminder
Data from the IMPACT Study on the comparisonof the renal tolerability assessment werepublished in Investigative Radiology last year
8/7/2019 Bracco Ppt Presentation_1
4/18
Confidential & Proprietary
Additional investigation objectives of theIMPACT Study
To prospectively compare the effects of iopamidol-370 and iodixanol-320 on: heart rate (H R) and
contrast enhancement efficacy
in renally-impaired patients undergoing contrast-enhanced, multidetector-row computed
tomography (CE-MDCT).
8/7/2019 Bracco Ppt Presentation_1
5/18
Confidential & Proprietary
Study Design
Multicenter (15 centers), double-blind, parallelgroup comparison
Patients were assigned randomly to receive
the intravenous (I.V.) injection of Iopamidol-370 or Visipaque TM 320 (iodixanol injection)
All groups and individuals associated with the
study remained blinded until the database waslocked and the data analyzed
Visipaque (iodixanol injection) is a trademark of GE Healthcare.
8/7/2019 Bracco Ppt Presentation_1
6/18
Confidential & Proprietary
Study Patients
A total of 166 patients, 18 years of age or older
with stable, pre-existing moderate-to-severe kidney disease
referred for CE-MDCT examinationof the liver or peripheral vasculature
8/7/2019 Bracco Ppt Presentation_1
7/18
Confidential & Proprietary
Contrast Injection Protocol
The total iodine dose was set at 40 gI for allpatients (equating to 108 mL of Iopamidol-370or 125 mL of Iodixanol-320)
Both contrast agents were injected via an 18-20-gauge IV angiocatheter at 4 mL/s
The injection of the contrast agents wasfollowed by a 20 mL saline flush at 4 mL/s
8/7/2019 Bracco Ppt Presentation_1
8/18
8/7/2019 Bracco Ppt Presentation_1
9/18
Confidential & Proprietary
Monitoring Heart Rate
Heart rate (HR) measured with patients insupine position (on CT table)
Baseline HR (bpm) was obtained within 5min before CM injection
HR was monitored continuously from start of CM injection for 5 min
Peak post-dose HR was recorded
8/7/2019 Bracco Ppt Presentation_1
10/18
Confidential & Proprietary
Measurement of Contrast Enhancement
Images from liver MDCT exams were independentlyevaluated by 2 expert radiologists: with > 1 5 years abdominal imaging experience, unaffiliated with study centers,
and fully blinded to the CM used
The blinded readers performed quantitative HounsfieldUnit (HU) measurements at 4 predefined regions of interest (ROIs):
Arterial phase: proximal abdominal aorta Portal venous phase: main portal vein, inferior vena
cava, and normal liver parenchyma
8/7/2019 Bracco Ppt Presentation_1
11/18
Confidential & Proprietary
Comparability of Study Groups
* Isovue is the Bracco trade name of Iopamidol in U.S.
*
8/7/2019 Bracco Ppt Presentation_1
12/18
Confidential & Proprietary
Contrast MediaHeart Rate Effects
8/7/2019 Bracco Ppt Presentation_1
13/18
Confidential & Proprietary
Effects on Heart Rate
8/7/2019 Bracco Ppt Presentation_1
14/18
Confidential & Proprietary
Effects on Heart Rate
8/7/2019 Bracco Ppt Presentation_1
15/18
Confidential & Proprietary
Contrast Enhancement
8/7/2019 Bracco Ppt Presentation_1
16/18
Confidential & Proprietary
RO I Reader Parameter Iopamidol370
Iodixanol320
Difference(IopamidolIodixanol )
9 5% CI p-value
Proximal Abdominal
Aorta
Reader1
N 56 5 9
Mean 30 1 .3 273.6
Lsmean 303.2 27 1 .8 3 1 .4 (6. 1 ,56. 8 )
0.02
SE 9 .2 8 .9
Reader2
N 55 5 9
Mean 300. 1 276.0
Lsmean 30 1 .9 275. 1 26. 8 (2.3,5 1 .3 )
0.03
SE 8 .9 8 .6
Arterial Phase
8/7/2019 Bracco Ppt Presentation_1
17/18
Confidential & Proprietary
RO I Reader Parameter Iopamidol370
Iodixanol320
Difference(IopamidolIodixanol )
9 5% CI p-value
LiverParenchyma
Reader1
N 55 60
Mean 11 3. 4 11 2.0
Lsmean 11 3. 4 111 .9 1 .4 (-5.5,8 .4 )
0.7
SE 2.5 2. 4
Reader2
N 56 6 1
Mean 111 .9 1 0 8 .5
Lsmean 11 2. 1 1 0 8 .3 3. 8 (-3.2,1 0.7 )
0.3
SE 2.5 2. 4
Portal Phase
8/7/2019 Bracco Ppt Presentation_1
18/18
Confidential & Proprietary
Conclusions of this study
Top Related